Fig 1: Effect of 5-HT1F receptor agonist on mitochondrial biogenesis in the spinal cord of neuropathic pain rats. (A) To determine whether 5-HT1F receptor agonist affect mitochondrial biogenesis in SNI rats, lasmiditan (100 μg, i. t.) was given once daily for five consecutive days starting from day 7. Two hours after the final administration, the L4–6 spinal cord was collected. The mtDNA copy number was significantly downregulated in SNI rats, which was reversed by Lasmiditan treatment (* p < 0.05, compared with Sham + Vehicle group, # p < 0.05 compared with SNI + Vehicle group, n = 6 in each group). (B) The protein level of PGC-1α was significantly downregulated in SNI rats, which was reversed by lasmiditan treatment (**** p < 0.0001 compared with Sham + Vehicle group, #### p < 0.0001 compared with SNI + Vehicle group, n = 6 in each group). (C) The protein level of NRF1 was significantly downregulated in SNI rats, which was reversed by lasmiditan treatment (**** p < 0.0001 compared with Sham + Vehicle group, #### p < 0.0001 compared with SNI + Vehicle group, n = 6 in each group). (D) The protein level of TFAM was significantly downregulated in SNI rats, which was reversed by lasmiditan treatment (**** p < 0.0001 compared with Sham + Vehicle group, #### p < 0.0001 compared with SNI + Vehicle group, n = 6 in each group).
Fig 2: Effect of 5-HT1F receptor agonist on PWT and mitochondrial biogenesis in naïve rats. (A) No significant change regarding PWT was observed after lasmiditan injection at any time of the observation period (p > 0.05 compared with Naïve + Vehicle group, n = 10 in each group). (B) No significant change regarding mtDNA copy number was observed after lasmiditan treatment (p > 0.05 compared with Naïve + Vehicle group, n = 6 in each group). (C) No significant change regarding the protein level of PGC-1α was observed after lasmiditan treatment (p > 0.05 compared with Naïve + Vehicle group, n = 6 in each group). (D) No significant change regarding the protein level of NRF1 was observed after lasmiditan treatment (p > 0.05 compared with Naïve + Vehicle group, n = 6 in each group). (E) No significant change regarding the protein level of TFAM was observed after lasmiditan treatment (p > 0.05 compared with Naïve + Vehicle group, n = 6 in each group).
Fig 3: Treatment with exogenous irisin increases mitochondrial content by promoting mitochondrial biogenesis after hepatic ischemia-reperfusion (I/R). Irisin treatment in mice was conducted by intravenous administration (250 μg/kg, a single dose) at the beginning of reperfusion. The liver tissues were harvested at 24 h after reperfusion. A, Liver mtDNA copy numbers assessed by quantitative polymerase chain reaction (qPCR). B, qPCR analysis of liver peroxisome proliferative activated receptor-γ (PPARγ) co-activator 1α (PGC-1α) levels. C and D, Western blot analysis of liver transcription factor (TFAM) expression. n = 6, mea ± SEM, *P < 0.05 versus sham group, #P < 0.05 versus vehicle group. E and F, MitoTracker Red CMXRos fluorescence staining and its fluorescence intensity of HL-7702 cells at 2 h after reoxygenation; G, qPCR analysis of PGC-1α levels in HL-7702 cells at 2 h and 8 h after reoxygenation. H and I, Western blot analysis of TFAM expression in HL-7702 cells at 2 h and 8 h after reoxygenation; J, ATP content of HL-7702 cells at 2 h and 8 h after reoxygenation. n = 3, mean ± SEM, *P < 0.05 versus sham group, #P < 0.05 versus H/R group.
Fig 4: mitoSIRF detects proteins bound to nascent mtDNA.(A and B) Representative images of MRE11-mitoSIRF assay or TFAM-mitoSIRF assay (sketch to the left) in SH2038 cells with antibody stain against mitochondria (mt-protein). Only cytoplasmic signals are considered. Note that fluorescent signals of costains are fainter when overlapping with MIRA signals, consistent with spatial co-occupancy. (C) Airyscan superresolution image of SH2038 cells with immunofluorescent stain against dsDNA and MRE11-mitoSIRF signals. (D) Quantification of MRE11-mitoSIRF signals overlapping (black) or not overlapping (gray) with dsDNA signals. (E) Airyscan superresolution image of MRE11-mitoSIRF in BJ fibroblasts with antibody stain against dsDNA. (F) Quantification of (E) MRE11-mitoSIRF signals overlapping (black) or not (gray) with dsDNA. (G) Representative images of RPA-mitoSIRF and TFAM mitoSIRF with 1 or 3 hours of EdU. (H) Quantification of (G). (I) Representative images of a MRE11-mitoSIRF 3 hours after mtOX (4 μM) treatment. Mirin (50 μM) was present throughout the experiment where indicated. (J) Quantification of (I). (K) Airyscan superresolution image of RAD51C-mitoSIRF in BJ fibroblasts with antibody stain against dsDNA. (L) Quantification of (K) RAD51C-mitoSIRF signals overlapping (black) or not (gray) with dsDNA. Bars represent the mean of compiled data from biological repeats. P values are derived using the Mann-Whitney test. ****P < 0.0001.
Fig 5: Effects of AAVi-Parkin administration on neuronal cell damage, mitochondrial ubiquitination and mitochondrial clearance in CA1 after ischemia with HPC.A Phase contrast and fluorescent images from coronal sections of CA1 following injection of AAVi-CON (a, b) or AAVi-Parkin (c, d) in Sham animals. White arrowhead shows the needle trace. Scale bar: 75 μm. B, C Representative immunoblots of PINK1 and Parkin expressions in CA1. Data are expressed as percentage of value of Sham animals. Each bar represents the mean ± SD. *p < 0.05 vs. Sham animals and #p < 0.05 vs. Sham group with AAVi-CON injection (n ≥ 4 in each group). D Representative microphotographs of cresyl violet staining and NeuN immunostaining in CA1 from rats administered bilaterally with either AAVi-CON or AAVi-Parkin at 7 d after reperfusion with hypoxia. Boxes indicate that the magnified regions displayed in the right panel. Scale bar: a, c, e, g, i, k, m, o: 250 μm; b, d, f, h, j, l, n, p: 25 μm. E, F Quantitative analyses of surviving and NeuN-positive cells in CA1. Each bar represents the mean ± SD. *p < 0.05 vs. Sham animals and #p < 0.05 vs. the same group with AAVi-CON administration (n = 6 in each group). G Western blot analyses of TOMM20, TIMM23, HSP60 and mtTFA in CA1. The histogram presents the quantitative analyses of TOMM20, TIMM23, HSP60, and mtTFA levels. Western blot analyses of PINK1, Parkin, and LC3 in the cytoplasmic fraction (H) and mitochondrial fraction (I) of CA1. The histogram presents the quantitative analyses of PINK1, Parkin, and the ratio of LC3-II/I. J Western blot analysis of ubiquitin in the mitochondrial fraction of CA1. The histogram presents the quantitative analysis of ubiquitin levels. Data are expressed as percentage of value of Sham animals. Each bar represents the mean ± SD. *p < 0.05 vs. Sham group and #p < 0.05 vs. the same group with AAVi-CON injection (n ≥ 4 in each group).
Supplier Page from Abcam for Anti-mtTFA antibody - Mitochondrial Marker